BRIEF published on 07/28/2026 at 15:25, 1 month 20 days ago Edison Research Analyzes BB Biotech's Robust Q2 Performance Investment Strategy Portfolio Expansion Market Outlook BB Biotech Q2 2026 Results
PRESS RELEASE published on 07/28/2026 at 15:20, 1 month 20 days ago Edison issues report on BB Biotech (BION) Edison issues favorable report on BB Biotech (BION) Q226 results, highlighting NAV growth, portfolio adjustments, and revised payout policy, supporting positive outlook for biotechnology investing Biotechnology Edison Report BB Biotech Q226 Results
BRIEF published on 07/24/2026 at 07:05, 1 month 25 days ago BB Biotech AG Reports Interim Gains and Adjusts Dividend Policy Dividend Policy Investment Portfolio Interim Report BB Biotech Net Gain
BRIEF published on 07/24/2026 at 07:05, 1 month 25 days ago BB Biotech Q2 2026: Robust NAV Performance Amid Strategic Investments Portfolio Diversification Dividend Policy Strategic Investments M&A Activity Biotechnology Performance
PRESS RELEASE published on 07/24/2026 at 07:00, 1 month 25 days ago EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy BB Biotech AG publishes its interim report for the first half of 2026, reporting a net gain and revising its dividend policy. Details at www.bbbiotech.ch Financial Results Investment Company Dividend Policy BB Biotech AG Interim Report
PRESS RELEASE published on 07/24/2026 at 07:00, 1 month 25 days ago BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning BB Biotech AG reports strong NAV outperformance in Q2 2026, driven by disciplined stock selection and portfolio positioning, new investments, and revised dividend policy Dividend Policy BB Biotech AG Stock Selection Q2 2026 NAV Outperformance
BRIEF published on 04/24/2026 at 07:05, 4 months 24 days ago BB Biotech AG Reports Q1 2026 Interim Results Drug Development Net Loss Investment Portfolio BB Biotech Q1 2026
BRIEF published on 04/24/2026 at 07:05, 4 months 24 days ago BB Biotech Q1 2026 Achievements and Strategic Shifts Net Asset Value Portfolio Repositioning New Investments BB Biotech Performance Dividend Inclusion
PRESS RELEASE published on 04/24/2026 at 07:00, 4 months 24 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report for the first quarter of 2026, showing a net loss of CHF 21 mn compared to CHF 241 mn in the same period of 2025 Investment Company BB Biotech AG Interim Report Results Loss
PRESS RELEASE published on 04/24/2026 at 07:00, 4 months 24 days ago BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning BB Biotech AG reports Q1 2026 results with share price outperformance, narrowing discount, and active portfolio repositioning. Eleven new investments made in biotech sector Share Price BB Biotech AG Investments Portfolio Repositioning Q1 2026
Published on 09/18/2026 at 06:30, 2 hours 31 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 8 hours 6 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 8 hours 36 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 10 hours 46 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/18/2026 at 08:40, 20 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 1,000 million Convertible Bonds due 2030 (ISIN DE000A30V5R1 – Common Code 258943848 – German Securities Code (WKN) A30V5R)
Published on 09/18/2026 at 08:40, 20 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 500 million Convertible Bonds due 2029 (ISIN DE000A3MP437 – Common Code 238511097 – German Securities Code (WKN) A3MP43)
Published on 09/18/2026 at 08:37, 23 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 750 million Convertible Bonds due 2028 (ISIN DE000A3H2WQ0 – Common Code 220637387 – German Securities Code (WKN) A3H2WQ)
Published on 09/18/2026 at 08:31, 29 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: 2025 consolidated revenue within target range; 2025 consolidated EBIT below forecast; outlook for fiscal year 2026
Published on 09/18/2026 at 08:10, 51 minutes ago NORMA Group successfully completes second public share buyback offer with a repurchase volume of approximately EUR 208 million
Published on 09/17/2026 at 17:40, 15 hours 21 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 15 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days 2 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
